Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 3 of 58, showing 10 Applications out of 576 total, starting on record 21, ending on 30

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

21.

ECCT/25/09/03   PRESERVE
    Partial breast re-irradiation using ultra hypofractionation (PRESERVE) Phase 2 multi-institutional study   
Principal Investigator(s)
1. Angela Waweru
Site(s) in Kenya
Aga Khan University Hospital
 
09-02-2026 View

22.

ECCT/25/09/01   VLA1553-404
    VLA1553-404: A Pragmatic Randomised Controlled Trial to Evaluate the Effectiveness and Safety of VLA1553 against Chikungunya Virus Disease   
Principal Investigator(s)
1. Prof. Videlis Nduba
Site(s) in Kenya
1. KEMRI-MTWAPA (Kilifi county)
 
21-01-2026 View

23.

ECCT/25/08/09   First-in-human (FIH) study
    A Phase 1, Randomized, Placebo-Controlled, Double Blind, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CLY-124 in Healthy Volunteers and Participants with Sickle Cell Disease   
Principal Investigator(s)
1. Dr Lucas Tina Otieno
Site(s) in Kenya
1. Victoria Biomedical Research Institute [VIBRI] (Kisumu county)
2. Strathmore University Medical Center [SUMC], Creates for Research in Therapeutic Sciences (Nairobi City county)
 
17-09-2026 View

24.

ECCT/25/08/08   PROPS Trial
    Efficacy of probiotic supplementation in preterm and small for gestational age infants. A multi-centre, placebo-controlled, individually-randomised trial   (Probiotics in preterm and small for gestational age infants, PROPS trial)   
Principal Investigator(s)
1. Maureen Muchela
Site(s) in Kenya
1. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
2. Homabay County Referral Hospital (Homa Bay county)
3. Kisii Teaching and Referral Hospital (Kisii county)
4. Migori County Referral Hospital (Migori county)
 
29-04-2026 View

25.

ECCT/25/08/07   ACCEDE Usability Study
    USABILITY, ACCEPTABILITY, FEASIBILITY AND COST OF CONTINUOUS GLUCOSE MONITORING BY PERSONS LIVING WITH TYPE 1 DIABETES MELLITUS, HEALTH CARE PROVIDERS AND CAREGIVERS AT THE PAEDIATRIC AND ADOLESCENT ENDOCRINOLOGY CLINIC IN KENYATTA NATIONAL HOSPITAL   
Principal Investigator(s)
1. Prisca Amolo
Site(s) in Kenya
Kenyatta National Hospital
 
10-12-2025 View

26.

ECCT/25/08/06   MK-8527-010
    A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis in Women   
Principal Investigator(s)
1. Irene Wambui Inwani
Site(s) in Kenya
1. UW-KNH; Rachuonyo County Hospital, Oyugis (Homa Bay county)
2. KEMRI-CMR-RCTP KEMRI CIS Building (Kisumu county)
3. Kargeno Research & Policy Hub (Kisumu county)
4. KEMRI-CCR-PHRD, Thika site (Kiambu county)
 
15-12-2025 View

27.

ECCT/25/08/05   Floral roll over study
    An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study.   
Principal Investigator(s)
1. Dr. Isaac Tsikhutsu
Site(s) in Kenya
1. KEMRI WALTER REED KERICHO (Kericho county)
2. Center for Research in Therapeutic Sciences (CREATES) (Kisumu county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. Gertrudes Childrens Hospital (Nairobi City county)
5. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
6. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
7. KEMRI Kondele Children\'s Hospital (Kisumu county)
 
09-02-2026 View

28.

ECCT/25/08/04   MK-8527-010 PrEP
    A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate the Efficacy and Safety of Oral MK-8527 Once-Monthly as HIV-1 Preexposure Prophylaxis in Cisgender Women    
Principal Investigator(s)
1. Nelly Rwamba Mugo
Site(s) in Kenya
1. KEMRI-CCR PHRD Thika (Kiambu county)
 
25-11-2025 View

29.

ECCT/25/08/03   Cabotegravir + Rilpivirine Lon
    A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human   Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Long acting Combination Therapy Studies   
Principal Investigator(s)
1. Loice Achieng Ombajo
Site(s) in Kenya
1. Aga Khan University Hospital (Nairobi City county)
2. Moi University Clinical Research Centre (Uasin Gishu county)
3. KEMRI-WRP (Kericho county)
4. Kenyatta National Hospital Comprehensive Care Centre (Nairobi City county)
 
15-12-2025 View

30.

ECCT/25/08/02   MK-8527-010
    A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis in Women.   
Principal Investigator(s)
1. Elizabeth Anne Bukusi
Site(s) in Kenya
1. KEMRI CMR RCTP (Kisumu county)
 
21-11-2025 View